...
首页> 外文期刊>The American journal of emergency medicine >Comparing the efficacy of intravenous tenoxicam, lornoxicam, and dexketoprofen trometamol for the treatment of renal colic
【24h】

Comparing the efficacy of intravenous tenoxicam, lornoxicam, and dexketoprofen trometamol for the treatment of renal colic

机译:静脉使用替诺昔康,氯诺昔康和右酮洛芬曲美他莫治疗肾绞痛的疗效比较

获取原文
获取原文并翻译 | 示例

摘要

Study Objective: The aim of this study was to compare the efficacy and safety of 3 nonsteroidal anti-inflammatory drugs - intravenous tenoxicam, lornoxicam, and dexketoprofen trometamol - for the treatment of patients with renal colic. Methods: We conducted a prospective double-blind randomized trial of consecutive adult patients who presented to the emergency department with a chief complaint of acute flank pain and had a clinical diagnosis of suspected acute renal colic. Patients were randomly allocated to receive an intravenous bolus of tenoxicam, lornoxicam, or dexketoprofen trometamol in a blinded fashion. Primary outcome measure of the study was visual analog scale (VAS) score difference at 30 minutes. Secondary outcome measures were VAS scores at 5, 15, and 120 minutes as well as rescue analgesic need at 30 minutes and adverse events during the follow-up period. Results: A total of 445 patients were screened, and 123 patients were enrolled in the study. The mean age was 36 ± 10 years. The mean reduction in VAS pain scores at 30 minutes was 42 ± 26 mm for tenoxicam, 57 ± 23 mm for lornoxicam, and 52 ± 25 mm for dexketoprofen (P = .047). Lornoxicam demonstrated the fastest rate of VAS score reduction over the first 30 minutes. The mean reduction values in VAS pain scores at 5, 15, and 120 minutes were similar among the 3 groups. Rescue analgesics at 30 minutes were required by 16 patients (39%) receiving tenoxicam, 10 patients (24%) receiving lornoxicam, and 8 patients (19%) receiving dexketoprofen (P = .121). No serious adverse events were observed. Conclusions: Intravenous tenoxicam, lornoxicam, and dexketoprofen are all effective in the treatment of renal colic, although lornoxicam appears to reduce VAS pain scores with the fastest rate in this comparison.
机译:研究目的:本研究的目的是比较3种非甾体类抗炎药-静脉使用Tenoxicam,氯诺昔康和右旋酮洛芬trometamol-治疗肾绞痛的疗效和安全性。方法:我们进行了一项前瞻性双盲随机试验,对连续成年患者进行了前瞻性双盲试验,这些患者在急诊科就主诉急性胁腹痛并具有可疑急性肾绞痛的临床诊断。随机分配患者以盲法接受替诺昔康,氯诺昔康或右酮洛芬曲美他莫的静脉推注。该研究的主要结局指标是30分钟时的视觉模拟量表(VAS)得分差异。次要结果指标是在5、15和120分钟时进行VAS评分,在30分钟时进行急救镇痛,以及随访期间的不良事件。结果:共筛选了445例患者,并纳入了123例患者。平均年龄为36±10岁。替诺昔康在30分钟时的VAS疼痛评分平均降低为42±26 mm(氯诺昔康)和57±23 mm(右酮洛芬)(P = .047)。 Lornoxicam在最初30分钟内显示出最快的VAS评分降低速度。 3组之间在5、15和120分钟时VAS疼痛评分的平均降低值相似。接受替诺昔康的16名患者(39%),接受氯诺昔康的10名患者(24%)和接受右酮洛芬的8名患者(19%)需要在30分钟时进行急救镇痛(P = .121)。没有观察到严重的不良事件。结论:静脉使用替诺昔康,氯诺昔康和右酮洛芬均能有效治疗肾绞痛,尽管在这种比较中,氯诺昔康似乎以最快的速度降低了VAS疼痛评分。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号